2024, January 31
Share this articleDos Sarbassov, Professor at the NU School of Sciences and Humanities and General Director of the National Laboratory Astana, held a small press conference where he spoke about the interim results of his research.
Sarbassov is working on a new drug for KRAS-mutant types of cancer. The drug has already passed the first stage of human trials on a group of 15 cancer patients. As a result, all of them observed a halt in the growth of cancer cells, and some even saw a decrease. Read more about the research from Informburo, Jibek Joly, 24.kz, Liter, Kazinform, and others.
